Endovia Health Sciences raises equity line cap to $135M

Q: How large is EDVA’s amended equity-line commitment?

The amended total maximum commitment is $135 million, increased from $35 million and inclusive of prior sales under the agreement.

The addendum also updates terms for facility sales in excess of the initial 10,875,000 shares sold and issued under the agreement.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Endovia Health Sciences, Inc. (EDVA) amended its equity line of credit agreement with C/M Capital Master Fund, LP on October 22, 2026, increasing the total maximum commitment from $35 million to $135 million, inclusive of prior sales under the agreement.

The addendum also updates terms for sales under the facility in excess of the initial 10,875,000 shares that were or are sold and issued under the agreement. The underlying Securities Purchase Agreement is dated September 19, 2025.

Filing Explained

The amendment expands capacity for additional share sales and issuance beyond the initial 10,875,000 shares, creating potential dilution; its $135 million maximum includes prior sales, and this filing does not state an amount drawn or proceeds received.

8-K Event Classification

2 items: 1.01, 9.01

2 items

Item 1.01 Entry into a Material Definitive Agreement Business

The company signed a significant contract such as a merger agreement, credit facility, or major partnership.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Original maximum commitment: $35 million Amended total maximum commitment: $135 million Initial shares: 10,875,000 shares

3 metrics

Original maximum commitment $35 million Under the ELOC Agreement before the addendum

Amended total maximum commitment $135 million Inclusive of prior sales under the ELOC Agreement

Initial shares 10,875,000 shares Initial shares sold and issued under the agreement; updated terms apply to sales in excess

Key Terms

equity line of credit facility, maximum commitment amount, Securities Purchase Agreement

3 terms

equity line of credit facility financial

"providing for an equity line of credit facility"

An equity line of credit facility is a financing agreement that lets a company raise cash on demand by issuing new shares to a lender or investor as draws are made, similar to a credit card that’s paid by giving up a small portion of ownership instead of cash. It matters to investors because it provides flexible cash when needed but increases the number of shares outstanding, which can dilute existing ownership and affect the stock price.

maximum commitment amount financial

"increase the total maximum commitment amount"

Securities Purchase Agreement financial

"Securities Purchase Agreement dated September 19, 2025"

A securities purchase agreement is a written contract between a buyer and a seller outlining the terms for buying or selling financial assets such as stocks or bonds. It specifies details like the price, quantity, and conditions of the transaction, similar to a shopping list with agreed-upon terms. For investors, it provides clarity and legal protection when transferring ownership of these financial instruments.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How large is EDVA’s amended equity-line commitment?

The amended total maximum commitment is $135 million, increased from $35 million and inclusive of prior sales under the agreement.

When do the updated EDVA equity-line terms apply?

They apply to sales under the amended agreement in excess of the initial 10,875,000 shares of common stock that were or are sold and issued under the agreement.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 10/27/2026 - 04:11 PM EDT Accepted by SEC EDGAR 10/27/2026 - 04:10 PM EDT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 22, 2026

ENDOVIA HEALTH SCIENCES, INC.

(Exact name of registrant as specified in its charter)

Nevada

001-40471

34-1720075

(State or other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

1112 N. Flagler Drive

Fort Lauderdale, Florida

33304

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (954) 648-7238

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value		EDVA		NYSE American LLC

Item 1.01 Entry into a Material Definitive Agreement.

On October 22, 2026, Endovia Health Sciences, a Nevada corporation (the “Company”) entered into an Addendum to that certain Securities Purchase Agreement dated September 19, 2025 providing for an equity line of credit facility (the “ELOC Agreement”) with C/M Capital Master Fund, LP (the “Addendum”), pursuant to which parties agreed to amend and supplement the ELOC Agreement to, among other things, increase the total maximum commitment amount from $35 million to $135 million, inclusive of prior sales under the ELOC Agreement. The Addendum also provides for certain updated terms for sales that are made under the ELOC Agreement, as amended by the Addendum, in excess of the initial 10,875,000 shares of the Company’s common stock which were or are sold and issued pursuant to the ELOC Agreement.

The ELOC Agreement was originally filed as Exhibit 10.3 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on September 25, 2025. The foregoing description of the Addendum does not purport to be complete and is qualified in its entirety by the full text of the Addendum which is filed as Exhibit 10.1 in this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit		Description
10.1		Addendum to ELOC Agreement
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ENDOVIA HEALTH SCIENCES, INC.

Date: October 27, 2026	By:	/s/ Brady Cobb
	Name:	Brady Cobb
	Title:	Interim Chief Executive Officer

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

4 documents

Agreements & Contracts

EX-10.1 EXHIBIT 10.1 46.2 KB